KALC 2025

Program at a Glance

The Schedule is tentative and subject to change.

Day 1, Thursday, November 6, 2025

KALC 2025 Program at a glace, Day1, Thursday, November 7, 2025
TIME	Room A	Room B	Room C
08:20-08:30	Opening
08:30-09:10	Satellite Symposium I (A)	Satellite Symposium I (B)	Satellite Symposium I (C)
09:10-09:20	Break
09:20-10:20	Session I (A) Lung Cancer and Risk Factors	Session I (B) Advanced Radiation Techniques and Technologies	Session I (C) Controversies and Future Directions of Lung Cancer Screening
10:20-10:35	Break
10:35-11:35	Session II (A) Partnering for Life: Creating a Seamless Journey Together	Session II (B) Latest Trends in Biomarker-Based Precision Medicine (KASTT)	Session II (C) Nodule Management and Early Diagnostic Strategies
11:35-11:50	Break
11:50-12:30	Plenary Session I
12:30-13:10	Luncheon Symposium I
13:10-13:30	Break
13:30-14:30	Session III (A) Thymic Epithelial Tumors: Multidisciplinary Approach	Session III (B) ADCs: Current Controversies	Session III (C) Interventional Pulmonology
14:30-14:45	Break
14:45-15:45	Session IV (A) The Evolving Landscape of Lung Cancer Surgery	Session IV (B) Oncogene Addicted NSCLC: Beyond EGFR and ALK	Session IV (C) Oral Presentation I
15:45-16:00	Break
16:00-16:40	Satellite Symposium II (A)	Satellite Symposium II (B)	Satellite Symposium II (C)

Day 2, Friday, November 7, 2025

KALC 2025 Program at a glace, Day1, Thursday, November 7, 2025
TIME	Room A	Room B	Room C
08:20-09:00	Satellite Symposium III (A)	Satellite Symposium III (B)	Satellite Symposium III (C)
09:00-09:10	Break
09:10-10:10	Session V (A) Novel immunotherapies beyond the PD1 pathway	Session V (B) Insights into Lung Cancer Pathology	Session V (C) Oral Presentation II
10:10-10:25	Break
10:25-11:25	Session VI (A) Challenges during Immunotherapy	Session VI (B) Unlocking Lung Cancer: Biological Discoveries	Session VI (C) Oral Presentation III
11:25-11:40	Break
11:40-12:20	Luncheon Symposium II
12:20-12:50	KALC General Meeting
12:50-13:30	Plenary Session II
13:30-13:50	Break
13:50-14:50	Session VII (A) Surgery in the Chemoimmunotherapy Era: Global Perspectives	Session VII (B) Biology and Novel Agents in SCLC	Session VII (C) EGFR-Mutant NSCLC: Optimal Regimen & Rationale
14:50-15:05	Break
15:05-16:05	Session VIII (A) Stage-Specific Considerations and Dilemmas	Session VIII (B) Decoding the Tumor Microenvironment: A High-Tech Revolution	Session VIII (C) Multi-Omics and AI-Driven Precision in Lung Cancer
16:05-16:30	Closing & Award Ceremony

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0186	14:45-14:55	Spatial transcriptomics reveals spatially diverse cancer-associated fibroblasts in lung squamous cell carcinoma linked to tumor progression	Kwon Joong Na	Seoul National University	Korea
A-0184	14:55-15:05	Single-cell RNA sequencing revealed that changes in monocytes are involved in the prognosis of durvalumab consolidation therapy following chemoradiotherapy	Duk Ki Kim	Chungnam National University	Korea
A-0105	15:05-15:15	Landscape of tumor heterogeneity and tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC)	Jong Yeob Kim	Feinberg School of Medicine, Northwestern University	USA
A-0127	15:15-15:25	Induction of malignant transformation in human bronchial epithelial cells and lung organoids by chronic exposure to whole cigarette smoke extract	Joo-Eun Lee	Chungnam National University	Korea
A-0057	15:25-15:35	Identification of GREM-1 and GAS6 as specific biomarkers for cancer-associated fibroblasts derived from patients with non-small cell lung cancer	Bo-Guen Kim	Kangbuk Samsung Medical Center	Korea
A-0042	15:35-15:45	Spatially defined co-culture model of non-small cell lung cancer organoids and cancer-associated fibroblasts to investigate phenotypic heterogeneity	Cheol-Kyu Park	Chonnam National University	Korea

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0226	09:10-09:20	Perioperative outcomes of neoadjuvant chemoimmunotherapy followed by surgery in stage II-III NSCLC: A real-world study	Junghee Lee	Samsung Medical Center	Korea
A-0214	09:20-09:30	Preliminary analysis of lazertinib consolidation therapy in patients with locally advanced, unresectable, EGFR mutated NSCLC following chemoradiation therapy: PLATINUM trial	Sung Yong Lee	Korea University	Korea
A-0204	09:30-09:40	What Is the Optimal Dose and Fractionation Schedule for Inoperable Node-Negative Large (>5 cm) Non-Small Cell Lung Cancer?	Ye Jin Yoo	Asan Medical Center	Korea
A-0108	09:40-09:50	Double lung transplantation in patients with metastatic lung-limited non-small cell lung carcinoma (NSCLC): A case series	Young Chae	Northwestern University Feinberg School of Medicine	USA
A-0069	09:50-10:00	Normal brain-sparing radiotherapy versus whole brain radiotherapy for multiple brain metastasis from non-small cell lung cancer	Sangjoon Park	Severance Hospital	Korea
A-0046	10:00-10:10	Refining patient selection for prophylactic cranial irradiation in limited-stage small-cell lung cancer: Insights from a Korean multi-institutional cohort study	Hye In Lee	Asan Medical Center	Korea

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0080	10:25-10:35	Real-world insights: Treatment patterns and overall survival in patients with small-cell lung cancer in South Korea a single center experience	Sehhoon Park	Samsung Medical Center, Sungkyunkwan University School of Medicine	Korea
A-0196	10:35-10:45	AI-powered pathologic response evaluation of post-neoadjuvant chemoimmunotherapy in NSCLC patients	Kwon Joong Na	Seoul National University	Korea
A-0167	10:45-10:55	Enhanced thrombopoiesis supplies PD-L1 to circulating immune cells via the generation of PD-L1-Expressing platelets in lung cancer patients	Jae Ho Cho	Chonnam National University Medical School	Korea
A-0230	10:55-11:05	Chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1	Ji Eun Shin	The Catholic University of Korea St. Vincent's Hospital	Korea
A-0131	11:05-11:15	Sequential hypofractionated radiotherapy followed by anti-PD-L1 atezolizumab for recurrent or refractory small cell lung cancer	Yang-Gun Suh	National Cancer Center	Korea
A-0035	11:15-11:25	Imaging trajectory of transformation into small-cell carcinomas from lung adenocarcinomas undergoing TKI treatment: radiomic prediction	Jihwan Choi	Samsung Medical Center	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0215	PE1-01	Engineering precision medicine for lung cancer: Antibody-mimetic scaffolds targeting EGFR	Tushar Kushwaha	All Institute of Medical Sciences	India
A-0128	PE1-02	TP53 mutations in Belarusian patients with non-small cell lung cancer	Hanna Shchayuk	Institute of Genetics and Cytology, National Academy of Sciences of Belarus	Belarus
A-0109	PE1-03	Optimized exosomal miRNA panels for early detection of non-small cell lung cancer	Da Hyun Kang	Chungnam National University	Korea
A-0060	PE1-04	Anticancer effect of Columbianadin against benzopyreneinduced lung cancer in rats: Role of PI3K/Akt/FoxO1 and inflammatory pathway	Vikas Kumar	Sam Higginbottom University of Agriculture, Technology & Sciences	India
A-0047	PE1-05	Role of exosomal proteins in brain-specific metastasis of lung cancer	Dong Ha Kim	Asan Medical Center	Korea
A-0238	PE1-06	The influence of knowledge and attitudes on smoking decisions: Case study of the Pandeyan Boyolai village community, Central Java.	Rinita Istiqomah	Yogyakarta State University	Indonesia
A-0237	PE1-07	Driver genes expression and fusions in patients with lung cancer	Yuliya Stankevich	Institute of Genetics and Cytology of the National Academy of Sciences of Belarus	Belarus
A-0233	PE1-08	Association between long non-coding RNA HOTAIR polymorphism and lung cancer risk: A meta-analysis	Farhana Sultana Mitu	Islamic University	Bangladesh
A-0232	PE1-09	A meta-analytic approach to find the association between polymorphism with in MicroRNAs and lung cancer risk	Md Abdullah Al Maruf	Islamic University	Bangladesh
A-0228	PE1-10	CTSC regulates cell growth in small cell lung cancer via YAP/PAR2 signaling pathway	Nayoung Kim	Chungnam National University Hospital	Korea
A-0208	PE1-11	Lung Organoid to understand mechanism of therapeutic resistance in lung cancer	Jinwook Choi	School of Life Sciences, Gwangju Institute of Science and Technology (gist)	Korea
A-0185	PE1-13	The impact of Living-Donor Lobar Lung Transplantation (LDLLT) procedure on the sexual function of donors and recipients: A systematic review	Rosinta Hotmaida P Purba	The Pranala Institute	Indonesia
A-0179	PE1-14	Loss of Cereblon (CRBN) enhances lung cancer cell migration and invasion through regulation of cystathionine -synthase (CBS)	Kihun Kim	Gwangju Institute of Science and Technology	Korea
A-0173	PE1-15	Parallel Accumulation-Serial Fragmentation for in-depth proteomic analysis of bronchoalveolar lavage fluid of non-small cell lung cancer	Seung Hyeun Lee	Kyung Hee University Medical Center	Korea
A-0164	PE1-16	Butanolic fraction of Asparagus racemosus root alters the JAK/STAT3 Signaling Pathway to mitigate metastasis, apoptosis, and proliferation in lung cancer	Niti Singh	Marlabs Innovation Pvt Ltd.	India
A-0161	PE1-17	Utilizing machine learning methodologies to forecast the occurence of lung cancer in patients of central region.	Manvendra Singh	Hmfa Miet	India
A-0160	PE1-18	Solid Lipid Nanoparticle of Ganodric acid in the treatment against benzopyreneinduced lung cancer in rats: Nrf2/HO-1 signaling pathway	V Kumar	Shalom Institute of Health & Allied Sciences	India
A-0156	PE1-19	Solid lipid nanoparticles of gallic acid enhances apoptosis and proliferation in rats to lessen lung cancer induced by diethylnitrosamine/2-acetylaminofluorene.	Deepika Singh	Shuats	India
A-0154	PE1-20	The incidence of hematologic paraneoplastic syndromes in newly diagnosed lung cancer patients	Roland Helmizar	Baiturrahmah University	Indonesia
A-0114	PE1-22	A pilot study to discover potential early NSCLC biomarkers in the Filipino secretome	Josemaria Alejandro Corpuz	University of the Philippines-Diliman	Philippines
A-0090	PE1-23	Recapitulation tumor microenvionments with lung cancer organoids for drug screening study	Insu Lee	Seoul National University Bundang Hospital	Korea
A-0088	PE1-24	What is our role to reduce lung cancer mortality rates?: Case studies of 7 countries with the highest lung cancer	Nadia Fazira	Andalas University	Indonesia
A-0087	PE1-25	ARAF p.S214C Mutation Enhances Sorafenib Response in Lung Cancer	Carol Lee	The Chinese University of Hong Kong	Hong Kong
A-0076	PE1-27	Enhancing tumoroid applications with regenix in advanced 3D cell culture models	Da Hye Song	Cellartgen	Korea
A-0068	PE1-28	Regenix in lung cancer PDX models: Advancing research and therapeutic potential	Da Hye Song	Cellartgen	Korea
A-0063	PE1-29	Synergistic anticancer effects of Niclosamide and Osimertinib: Repurposing drugs in autophagy for the treatment of EGFR-mutant lung cancer cells	Yuan-Ming Tsai	Tri-Service General Hospital, National Defense Medical Center	Taiwan
A-0051	PE1-30	Identification of Guanine-quadruplex forming DNA aptamer: A promising therapeutic strategy for EGFR overexpressed non-small cell lung cancer	Deepa Singh	All Institute of Medical Sciences	India
A-0050	PE1-31	Austrian biobanking and biomolecular resources research infrastructure - Important partner for research on biological samples	Luka Brcic	Medical University of Graz	Austria
A-0049	PE1-32	Clinical and genomic features of different KRAS Subtypes in non-small cell lung cancer	Soo Han Kim	Pusan National University Hospital	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0151	PE1-34	Network pharmacology study revealed the multitargets anticancer mechanism of sesamin in NSCLC	Reny Rosalina	University of Palangka Raya	Indonesia
A-0250	PE1-35	Utilizing machine learning algorithms for enhanced lung cancer diagnosis through imaging biomarkers	Divo Helmizar	Stan Jakarta	Indonesia
A-0239	PE1-36	Deep-learning model for personalized recurrence prediction in early-stage non-small cell lung cancer	Daehwan Lee	Spidercore Inc.	Korea
A-0093	PE1-38	Increased risk of lung cancer in individuals with nontuberculous mycobacterial pulmonary disease: A Korean population-based study	Dongwon Park	Hanyang University Medical Center	Korea
A-0086	PE1-39	Deep-learning-driven prediction of lung cancer recurrence using integrated immune profiling and radiomic features from computed tomography scans	Rifaldy Fajar	Yogyakarta State University	Indonesia

Others
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0064	PE1-40	Harnessing computer-aided drug discovery for the development of potent allosteric inhibitors targeting EGFR in NSCLC	Mdaliasif Noor	Chonbuk National University Hospital	Korea
A-0120	PE1-42	The association between prevalence of tobacco use, nitrous oxide emissions and current health expenditure toward lung cancer in asian countries	Devi Yulia Rahmi	Universitas Andalas	Indonesia
A-0139	PE1-43	Self efficacy and quality of life in lung cancer patients: Systematic reviews	Mega Dwi Septivani	Padang State Polytechnic	Indonesia
A-0166	PE1-44	Revealed intermittent fasting benefit: How does the systematic review suggest lung cancer patients should undergo the most effective fasting?	Yesika Simbolon	Atmajaya University	Indonesia

Mesothelioma / Thymic & Other Thoracic Malignancies
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0126	PE2-07	Pediatric mesothelioma: a case report	Heae Surng Park	Ewha Womans University Medical Center	Korea
A-0125	PE2-08	The impact of prevalence of annual freshwater withdrawals, drinking water services and air pollution toward mesothelioma cancer	Ferza Alfath	Alumnus Universitas Andalas	Indonesia
A-0118	PE2-09	Characterization of tumor-infiltrating B cells in malignant pleural mesothelioma and thymic carcinoma using single-cell RNA sequencing and deep learning	Sahnaz Vivinda Putri	International University Semen	Indonesia
A-0020	PE2-10	Well differentiated papillary mesothelial tumor from retrospective diagnosis for 10 years (2013 - 2023)	Nguyen Son Lam	Pham Ngoc Thach Hospital	Vietnam

Advanced Non-Small Cell Lung Cancer / Chemotherapy / Targeted Therapy / Immunotherapy
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0133	PE3-01	Targeting EGFR and its mutations in peatland fire-induced lung cancer: The therapeutic potential of Kalimantan's endemic plant compounds	Amanda Natania Gracia	Faculty of Mathematics and Natural Sciences, University of Palangka Raya	Indonesia
A-0082	PE3-02	Development of a novel inhibitor against nRAS-mutated lung cancers	Vikas Kumar	Aiims New Delhi	India
A-0059	PE3-03	Health-related quality of life with tepotinib in METex14 skipping NSCLC with brain, liver, adrenal or bone metastases: VISION trial	Beung Chul Ahn	Research Institute and Hospital of National Cancer Center	Korea
A-0252	PE3-04	Unlocking the potential of fasting to optimize chemotherapy outcomes in lung cancer: A bibliometric exploration	Fairuz Tsuraya Ramadhani	Universitas Palangka Raya	Indonesia
A-0224	PE3-05	A study to evaluate the effectiveness of exosomal proteins as biomarkers in non-small cell lung carcinoma	Aashal Bhavesh Shah	Gmers Medical College and Hospital	India
A-0205	PE3-06	Efficacy of Nivolumab in patients with recurrent advanced nonsmall cell lung cancer in Indian population	Jatinkumar Veljibhai Dhanani	Gmers Medical College, Navsari	India
A-0201	PE3-07	Evaluating the efficacy of sequential IL-6 and PD-1 inhibitor treatment in murine lung cancer: Immune modulation and tumor size reduction	Soyun Kim	Chungnam National University Hospital	Korea
A-0169	PE3-08	Delta-He as a novel prognostic biomarker in NSCLC patients treated with PD-1/PD-L1 inhibitors	Green Hong	Chungnam National University Hospital	Korea
A-0157	PE3-09	Bioinformatics identification of potent siRNAs targeting vscular endothelial growth factor receptor and mesenchymal-epithelial transition factor for non-small cell lung cancer	Rian Ka Praja	Universitas Palangka Raya	Indonesia
A-0122	PE3-10	AI-driven predictive model of ALK inhibitor responses merging single-cell RNA sequencing with radiogenomics in advanced non-small cell lung cancer	Prihantini Prihantini	Bandung Institute of Technology	Indonesia
A-0116	PE3-11	Impact of antibiotic exposure on the effectiveness of immune checkpoint inhibitors in patients with non-small cell lung cancer	Myeong Geun Choi	Ewha Womans University Mokdong Hospital	Korea
A-0089	PE3-12	Blood plasma proteomic-based identification and characterization of aberrantly expressed proteins in EGFR TKI resistant late-stage NSCLC patients	Ferdinand Mira	Institute of Chemistry, University of the Philippines, Diliman	Philippines
A-0065	PE3-13	Analysis of clinical characteristics and survival after completion of two years of immune checkpoint inhibitor treatment in advanced NSCLC	Kyoungmin Lee	Korea University Guro Hospital	Korea

Palliative Care
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0115	PE3-14	Digital aging and mental health deteriorationsof among Indonesian elderly with lung cancer: A psychosocioeconomic analysis	Lintong Hottua Simbolon	The Pranala Institute	Indonesia
A-0256	PE3-15	The significance of music-based interventions in lung cancer patients in palliative care : A bibliometric analysis	Mery Enjelica Cristin	Universitas Palangka Raya	Indonesia
A-0249	PE3-16	Music therapy and spiritual nursing care for lung cancer sufferers in Indonesia post surgery	Yusril Yusril	Uin Sjech M. Djamil Djambek Bukittinggi	Indonesia
A-0241	PE3-17	Palliative care for lung cancer patients: Before and during the COVID-19 pandemic	Yusril Yusril	Uin Sjech M. Djamil Djambek Bukittinggi	Indonesia
A-0213	PE3-18	Quality of life among chronic lung disease patients in Indonesia: Insights from the Indonesia family life survey	Derizal Derizal	Ip Trisakti	Indonesia
A-0207	PE3-19	Analysis of health management of mesothelioma patients in Indonesia, including early diagnosis, treatment, and palliative support.	Andi Makkasau Andi Ureng	Alami Gsb	Indonesia
A-0198	PE3-20	Best nudge to influence people's behaviour for better off: Choices architecture on lung cancer prevention?	Helen Try Juniasti	Cendrawasih University	Indonesia
A-0165	PE3-21	Prevention and treatment of lung disease disease: How community-based health care take the important role among 17k islands in Indonesia	Hepri Ardianson Purba	The Pranala Institute	Indonesia